OBJECTIVE: It has been suggested that neurocognitive impairment is a core deficit in schizophrenia. However, it appears that some patients with schizophrenia have intelligence quotients (IQs) in the superior range. In this study, we sought out schizophrenia patients with an estimated premorbid Intelligence Quotient (IQ) of at least 115 and studied their neuropsychological profile. METHOD: Thirty-four patients meeting diagnostic criteria for schizophrenia or schizoaffective disorder, as defined by the Diagnostic and Statistical Manual of Mental Disorders (4th ed.; DSM-IV), with mean estimated premorbid IQ of 120, were recruited and divided into two subgroups, according to whether or not their IQ had declined by at least 10 points from their premorbid estimate. Their performance on an extensive neuropsychological battery was compared with that of 19 IQ-matched healthy controls and a group of 16 "typical" schizophrenia patients with estimated premorbid IQ <110, using one way ANOVAs and profile analysis using MANOVAs. RESULTS: Schizophrenia patients whose estimated premorbid and current IQ both lay in the superior range were statistically indistinguishable from IQ-matched healthy controls on all neurocognitive tests. However, their profile of relative performance in subtests was similar to that of typical schizophrenia patients. Patients with superior premorbid IQ and evidence of intellectual deterioration had intermediate scores. CONCLUSIONS: Our results confirm the existence of patients meeting DSM-IV diagnostic criteria for schizophrenia who have markedly superior premorbid intellectual level and appear to be free of gross neuropsychological deficits. We discuss the implications of these findings for the primacy of cognitive deficits in schizophrenia.
OBJECTIVE: It has been suggested that neurocognitive impairment is a core deficit in schizophrenia. However, it appears that some patients with schizophrenia have intelligence quotients (IQs) in the superior range. In this study, we sought out schizophreniapatients with an estimated premorbid Intelligence Quotient (IQ) of at least 115 and studied their neuropsychological profile. METHOD: Thirty-four patients meeting diagnostic criteria for schizophrenia or schizoaffective disorder, as defined by the Diagnostic and Statistical Manual of Mental Disorders (4th ed.; DSM-IV), with mean estimated premorbid IQ of 120, were recruited and divided into two subgroups, according to whether or not their IQ had declined by at least 10 points from their premorbid estimate. Their performance on an extensive neuropsychological battery was compared with that of 19 IQ-matched healthy controls and a group of 16 "typical" schizophreniapatients with estimated premorbid IQ <110, using one way ANOVAs and profile analysis using MANOVAs. RESULTS:Schizophreniapatients whose estimated premorbid and current IQ both lay in the superior range were statistically indistinguishable from IQ-matched healthy controls on all neurocognitive tests. However, their profile of relative performance in subtests was similar to that of typical schizophreniapatients. Patients with superior premorbid IQ and evidence of intellectual deterioration had intermediate scores. CONCLUSIONS: Our results confirm the existence of patients meeting DSM-IV diagnostic criteria for schizophrenia who have markedly superior premorbid intellectual level and appear to be free of gross neuropsychological deficits. We discuss the implications of these findings for the primacy of cognitive deficits in schizophrenia.
Authors: Olav B Smeland; Shahram Bahrami; Oleksandr Frei; Alexey Shadrin; Kevin O'Connell; Jeanne Savage; Kyoko Watanabe; Florian Krull; Francesco Bettella; Nils Eiel Steen; Torill Ueland; Danielle Posthuma; Srdjan Djurovic; Anders M Dale; Ole A Andreassen Journal: Mol Psychiatry Date: 2019-01-04 Impact factor: 15.992
Authors: Anja Vaskinn; Torill Ueland; Ingrid Melle; Ingrid Agartz; Ole A Andreassen; Kjetil Sundet Journal: Front Psychiatry Date: 2014-05-07 Impact factor: 4.157
Authors: Rudolf Uher; Jill Cumby; Lynn E MacKenzie; Jessica Morash-Conway; Jacqueline M Glover; Alice Aylott; Lukas Propper; Sabina Abidi; Alexa Bagnell; Barbara Pavlova; Tomas Hajek; David Lovas; Kathleen Pajer; William Gardner; Adrian Levy; Martin Alda Journal: BMC Psychiatry Date: 2014-12-02 Impact factor: 3.630
Authors: Emily P Hedges; Hannah Dickson; Stefania Tognin; Gemma Modinos; Mathilde Antoniades; Mark van der Gaag; Lieuwe de Haan; Patrick McGorry; Christos Pantelis; Anita Riecher-Rössler; Rodrigo Bressan; Neus Barrantes-Vidal; Marie-Odile Krebs; Merete Nordentoft; Stephan Ruhrmann; Gabriele Sachs; Bart P Rutten; Jim van Os; Lucia R Valmaggia; Philip McGuire; Matthew J Kempton Journal: Schizophr Res Cogn Date: 2021-10-28
Authors: Madeline H Meier; Avshalom Caspi; Abraham Reichenberg; Richard S E Keefe; Helen L Fisher; HonaLee Harrington; Renate Houts; Richie Poulton; Terrie E Moffitt Journal: Am J Psychiatry Date: 2014-01 Impact factor: 18.112
Authors: R Walter Heinrichs; Farena Pinnock; Eva Muharib; Leah Hartman; Joel Goldberg; Stephanie McDermid Vaz Journal: Schizophr Res Cogn Date: 2015-11-19